Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL910075 | 0.99 | TOP2A (0.63) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL910290 | 0.97 | TOP2A (0.60) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL910407 | 0.97 | TOP2A (0.60) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL909969 | 0.96 | TOP2A (0.59) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL910265 | 0.96 | TOP2A (0.59) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL3327786 | 0.94 | TOP2A (0.73) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL3324515 | 0.94 | TOP2A (0.73) | TOP2AKCNH2SLC2A1 | |
| SCHEMBL3328140 | 0.94 | TOP2A (0.73) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL3327282 | 0.93 | TOP2A (0.72) | TOP2AKCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL3328877 | 0.93 | TOP2A (0.72) | TOP2AKCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | claimed |
| EP-2238138-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | claimed |
| WO-2009087153-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | claimed |
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009087153-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NRDC, NCL, NPM1 | TOP2A 96/4885KCNH2 3726/4885SLC2A1 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.